Form 4: Roivant Director Keith Manchester Receives Equity Award

Roivant Sciences Director Keith Manchester was granted an annual equity award of restricted stock units and stock options, vesting in 2026.

Summary

• Keith S. Manchester, a Director of Roivant Sciences Ltd. (ROIV), received an annual equity award.
• The award includes 14,524 Common Shares in the form of Restricted Stock Units (RSUs) granted on September 10, 2025, with a price of $0.
• The RSUs are scheduled to vest 100% on September 10, 2026, contingent on continuous service.
• Additionally, 33,726 stock options to purchase Common Shares were granted on September 10, 2025, with an exercise price of $13.77.
• These stock options are scheduled to vest and become exercisable 100% on September 10, 2026, also subject to continuous service, and expire on September 9, 2035.
• Following these transactions, Mr. Manchester beneficially owns 1,948,403 Common Shares directly and 33,726 stock options directly.

Sentiment

Score: 7

Explanation: The filing reflects standard, expected compensation for a director, aligning their interests with shareholders. This is generally viewed positively as a routine governance practice.

Positives

• The equity awards align the director's financial interests with those of the shareholders, incentivizing long-term performance.
• The awards are part of the company's established 2021 Equity Incentive Plan and Non-Employee Director Compensation Policy, indicating a structured approach to executive and director compensation.

Future Outlook

The vesting schedule for the equity awards on September 10, 2026, implies an expectation of Keith S. Manchester's continuous service as a director through that date.

Industry Context

This filing represents a routine annual equity compensation for a non-employee director, a common practice across publicly traded companies in the biotechnology and pharmaceutical sectors to attract and retain experienced board members and align their interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The equity awards align the director's interests with long-term shareholder value, potentially leading to more focused governance and strategic decisions.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• Keith S. Manchester's continued service as a director through September 10, 2026, for the equity awards to fully vest.

Key Dates

Recommendation

This Form 4 filing details a routine annual equity compensation for a director, which is an expected part of corporate governance and compensation practices. It does not contain new material information that would fundamentally alter the investment thesis or warrant a change in stock recommendation based solely on this disclosure.

Keywords

Roivant Sciences, ROIV, Keith Manchester, Director Compensation, Equity Award, Restricted Stock Units, Stock Options, Insider Transaction, Form 4